Base de dados : MEDLINE
Pesquisa : D03.383.533.640.900 [Categoria DeCS]
Referências encontradas : 210 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 21 ir para página                         

  1 / 210 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:29368813
[Au] Autor:Matthews PRL; Horder J; Pearce M
[Ad] Endereço:North Kildare Mental Health Service, Kildare West Wicklow MHS, Celbridge Community Health Centre, Shackleton Road, Celbridge, Co. Kildare, Ireland.
[Ti] Título:Selective noradrenaline reuptake inhibitors for schizophrenia.
[So] Source:Cochrane Database Syst Rev;1:CD010219, 2018 Jan 25.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Schizophrenia is frequently a chronic and disabling illness with a heterogeneous range of symptoms. The positive symptoms usually respond to antipsychotics but the cognitive and negative symptoms of schizophrenia are difficult to treat with conventional antipsychotics and significantly impact on quality of life and social outcomes. Selective noradrenaline reuptake inhibitors (NRIs) increase prefrontal dopamine and noradrenaline levels without significantly affecting subcortical dopamine levels, making them an attractive candidate for treating cognitive and negative symptoms. OBJECTIVES: To investigate the effects of selective noradrenaline reuptake inhibitors (NRIs), compared with a placebo or control treatment, for people with schizophrenia. SEARCH METHODS: We searched the Cochrane Schizophrenia Group's Trials Register (up to 7 February 2017) which is based on regular searches of MEDLINE, Embase, CINAHL, BIOSIS, AMED, PubMed, PsycINFO, and registries of clinical trials. There are no language, date, document type, or publication status limitation for inclusion of records into the register. We inspected references of all included studies for further relevant studies. SELECTION CRITERIA: We included randomised controlled trials (RCTs) comparing NRIs with either a control treatment or placebo for people with schizophrenia or related disorders (such as schizoaffective disorder) by any means of diagnosis. We included trials that met our selection criteria and provided useable information. DATA COLLECTION AND ANALYSIS: We independently inspected all citations from searches, identified relevant abstracts, and independently extracted data from all included studies. For binary data we calculated risk ratio (RR), for continuous data we calculated mean difference (MD), and for cognitive outcomes we derived standardised mean difference (SMD) effect sizes, all with 95% confidence intervals (CI) and using a random-effects model. We assessed risk of bias for the included studies and used the GRADE approach to produce a 'Summary of findings' table which included our prespecified main outcomes of interest. MAIN RESULTS: Searching identified 113 records. We obtained the full text of 48 of these records for closer inspection. Sixteen trials, randomising a total of 919 participants are included. The majority of trials included adults with schizophrenia or similar illness who were inpatients, and while they were poorly characterised, most appeared to include patients with a chronic presentation. The intervention NRI in nine of the 16 trials was reboxetine, with atomoxetine and viloxazine used in the remaining trials. 14 trials compared NRIs with placebo. Only two trials provided data to compare NRIs against an active control and both compared reboxetine to citalopram but at 4 weeks and 24 weeks respectively so they could not be combined in a meta-analysis.One trial was described as 'open' and we considered it to be at high risk of bias for randomisation and blinding, three trials were at high risk of bias for attrition, six for reporting, and two for other sources of bias. Our main outcomes of interest were significant response or improvement in positive/negative mental state, global state and cognitive functioning, average cognitive functioning scores, significant response or improvement in quality of life and incidence of nausea. All data for main outcomes were short term.NRIs versus placeboMental state results showed significantly greater rates of improvement in negative symptoms scores (1 RCT, n = 50; RR 3.17, 95% CI 1.52 to 6.58; very low quality evidence) with NRIs on the PANSS negative. No data were reported for significant response or improvement in positive symptoms, but average endpoint PANSS positive scores were available and showed no difference between NRIs and placebo (5 RCTs, n = 294; MD -0.16, 95% CI -0.96 to 0.63; low-quality evidence). Improvement in clinical global status was similar between groups (1 RCT, n = 28; RR 0.99, 95% CI 0.45 to 2.20; very low quality evidence). Significant response or improvement in cognitive functioning data were not reported. Average composite cognitive scores showed no difference between NRIs and placebo (4 RCTs, n = 180; SMD 0.04, 95% CI -0.28 to 0.36; low-quality evidence). Significant response or improvement in quality of life data were not reported, however average endpoint scores from the GQOLI-74 were reported. Those receiving NRIs had better quality of life scores compared to placebo (1 RCT, n = 114; MD 9.36, 95% CI 7.89 to 10.83; very low quality evidence). All-cause withdrawals did not differ between the treatment groups (8 RCTs, n = 401, RR 0.94 95% CI 0.63 to 1.39; moderate-quality evidence). Rates of nausea were not greater with NRIs (3 RCTs, n = 176; RR 0.49, 95% CI 0.10 to 2.41; low-quality evidence). AUTHORS' CONCLUSIONS: Our results provide tentative very low quality evidence that compared to placebo, NRIs (specifically reboxetine) may have a benefit on the negative symptoms of schizophrenia. Limited evidence also suggests that NRIs have no effect on the positive symptoms of schizophrenia or cognitive functioning. NRIs appear generally well tolerated with no real differences in adverse effects such as nausea noted between NRIs and placebo. However, these results are based on short-term follow-up and are poor quality - there is need for more good-quality evidence. A large RCT of reboxetine over a longer period of time, focusing specifically on negative and cognitive symptoms as well as more detailed and comprehensive reporting of outcomes, including adverse events, is required.
[Mh] Termos MeSH primário: Inibidores da Captação Adrenérgica/uso terapêutico
Esquizofrenia/tratamento farmacológico
Inibidores da Recaptação de Serotonina e Norepinefrina/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Cloridrato de Atomoxetina/uso terapêutico
Citalopram/uso terapêutico
Cognição/efeitos dos fármacos
Seres Humanos
Morfolinas/uso terapêutico
Qualidade de Vida
Ensaios Clínicos Controlados Aleatórios como Assunto
Viloxazina/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Adrenergic Uptake Inhibitors); 0 (Morpholines); 0 (Serotonin and Noradrenaline Reuptake Inhibitors); 0DHU5B8D6V (Citalopram); 57WVB6I2W0 (Atomoxetine Hydrochloride); 5I5Y2789ZF (Viloxazine); 947S0YZ36I (reboxetine)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180126
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD010219.pub2


  2 / 210 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:18471711
[Au] Autor:Tan MC; Castaldo ET; Gao F; Chari RS; Linehan DC; Wright JK; Hawkins WG; Siegel BA; Delbeke D; Pinson CW; Strasberg SM
[Ad] Endereço:Section of Hepato-Pancreato-Biliary Surgery, Department of Surgery, Washington University in Saint Louis, St Louis, MO 63110, USA.
[Ti] Título:A prognostic system applicable to patients with resectable liver metastasis from colorectal carcinoma staged by positron emission tomography with [18F]fluoro-2-deoxy-D-glucose: role of primary tumor variables.
[So] Source:J Am Coll Surg;206(5):857-68; discussion 868-9, 2008 May.
[Is] ISSN:1879-1190
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The purpose of this study was to develop a prognostic system applicable to patients with hepatic metastasis from colorectal cancer in whom extrahepatic disease was excluded by preoperative PET with [(18)F]fluoro-2-deoxy-D-glucose (FDG-PET). Data from two institutions were analyzed separately and together to improve general applicability of results. STUDY DESIGN: Data were analyzed for 285 consecutive patients undergoing liver resection for colorectal metastases from 1995 to 2005 at 2 institutions routinely using preoperative FDG-PET with. Fifteen clinicopathologic variables of the primary and secondary tumors were examined to identify factors predictive of survival. RESULTS: Outcomes were correlated with poorly differentiated tumor grade in both data sets. Because patients with poorly differentiated tumors comprised a small proportion (16%) of the population, patients with well-differentiated or moderately differentiated tumors were analyzed independently. In this subgroup, positive lymph node status in the primary colorectal tumor resection specimen was the only characteristic that predicted survival of patients in both institutions. Consequently, patients were sorted into three prognostic categories: poor tumor differentiation; well-differentiated or moderately differentiated tumors and node positive; and well-differentiated or moderately differentiated tumors and node negative. These groups had significantly different overall survival on Kaplan-Meier analysis (p=0.0014). CONCLUSIONS: In patients with colorectal liver metastases staged with FDG-PET with overall survival can be predicted directly from data in the pathology report of the colorectal primary tumor. This study also indicates the need for new molecular tumor markers of prognosis to complement clinicopathologic markers if the goal of prediction of outcomes in individual patients is to be reached.
[Mh] Termos MeSH primário: Neoplasias Colorretais/cirurgia
Neoplasias Hepáticas/cirurgia
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Neoplasias Colorretais/diagnóstico por imagem
Neoplasias Colorretais/mortalidade
Neoplasias Colorretais/patologia
Feminino
Fluordesoxiglucose F18
Seres Humanos
Neoplasias Hepáticas/diagnóstico por imagem
Neoplasias Hepáticas/mortalidade
Neoplasias Hepáticas/secundário
Masculino
Meia-Idade
Estadiamento de Neoplasias
Tomografia por Emissão de Pósitrons
Prognóstico
Compostos Radiofarmacêuticos
Viloxazina
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Radiopharmaceuticals); 0Z5B2CJX4D (Fluorodeoxyglucose F18); 5I5Y2789ZF (Viloxazine)
[Em] Mês de entrada:0805
[Cu] Atualização por classe:161124
[Lr] Data última revisão:
161124
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:080513
[St] Status:MEDLINE
[do] DOI:10.1016/j.jamcollsurg.2007.12.023


  3 / 210 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:10771496
[Au] Autor:Leroi AM; Lalaude O; Antonietti M; Touchais JY; Ducrotte P; Menard JF; Denis P
[Ad] Endereço:Groupe de Recherche sur l'Appareil Digestif, Policlinique, Hôpital Charles Nicolle, Rouen, France.
[Ti] Título:Prolonged stationary colonic motility recording in seven patients with severe constipation secondary to antidepressants.
[So] Source:Neurogastroenterol Motil;12(2):149-54, 2000 Apr.
[Is] ISSN:1350-1925
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The aim of this study was to determine whether the colonic motor profile of seven patients with constipation secondary to antidepressants differed from the motility of seven patients with idiopathic constipation and seven healthy volunteers. All constipated patients had very severe constipation. Colonic manometric recordings were performed for 24 h. The number of high amplitude propagating contractions (HAPC) was lower in the two groups of constipated patients than in controls. No HAPC were observed in 5/7 patients with constipation secondary to antidepressants and in 1/7 patients with idiopathic constipation. The overall area under the curve (AUC) in the left colon was lower in the two constipated patient groups than in controls. AUC increased after a 1000-kcal standard meal given at noon in controls but not in the two groups of constipated patients. In conclusion, in patients with constipation secondary to antidepressants, the overall AUC was as poor as in patients with idiopathic constipation, and no colonic response to eating was observed. Moreover, the number of HAPC was more markedly decreased in patients with constipation secondary to antidepressants than in patients with idiopathic constipation.
[Mh] Termos MeSH primário: Antidepressivos/efeitos adversos
Constipação Intestinal/induzido quimicamente
Transtorno Depressivo/tratamento farmacológico
Motilidade Gastrointestinal/efeitos dos fármacos
[Mh] Termos MeSH secundário: Adulto
Amitriptilina/efeitos adversos
Amitriptilina/farmacologia
Amitriptilina/uso terapêutico
Antidepressivos/farmacologia
Antidepressivos/uso terapêutico
Transtornos de Ansiedade/complicações
Catárticos/uso terapêutico
Antagonistas Colinérgicos/efeitos adversos
Antagonistas Colinérgicos/farmacologia
Antagonistas Colinérgicos/uso terapêutico
Clomipramina/efeitos adversos
Clomipramina/farmacologia
Clomipramina/uso terapêutico
Colo/efeitos dos fármacos
Colo/fisiopatologia
Colonoscopia
Constipação Intestinal/tratamento farmacológico
Constipação Intestinal/fisiopatologia
Transtorno Depressivo/complicações
Ingestão de Alimentos
Impacção Fecal/induzido quimicamente
Impacção Fecal/tratamento farmacológico
Impacção Fecal/fisiopatologia
Feminino
Seres Humanos
Masculino
Manometria
Maprotilina/efeitos adversos
Maprotilina/farmacologia
Maprotilina/uso terapêutico
Meia-Idade
Transtornos do Humor/complicações
Contração Muscular
Paroxetina/efeitos adversos
Paroxetina/farmacologia
Paroxetina/uso terapêutico
Inibidores da Captação de Serotonina/efeitos adversos
Inibidores da Captação de Serotonina/farmacologia
Inibidores da Captação de Serotonina/uso terapêutico
Tiazepinas/efeitos adversos
Tiazepinas/farmacologia
Tiazepinas/uso terapêutico
Viloxazina/efeitos adversos
Viloxazina/farmacologia
Viloxazina/uso terapêutico
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antidepressive Agents); 0 (Cathartics); 0 (Cholinergic Antagonists); 0 (Serotonin Uptake Inhibitors); 0 (Thiazepines); 0T493YFU8O (tianeptine); 1806D8D52K (Amitriptyline); 2U1W68TROF (Maprotiline); 41VRH5220H (Paroxetine); 5I5Y2789ZF (Viloxazine); NUV44L116D (Clomipramine)
[Em] Mês de entrada:0006
[Cu] Atualização por classe:141120
[Lr] Data última revisão:
141120
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:000420
[St] Status:MEDLINE


  4 / 210 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:10465409
[Au] Autor:Corral C; Lissavetzky J; Manzanares I; Darias V; Expósito-Orta MA; Martïn Conde JA; Sánchez-Mateo CC
[Ad] Endereço:Instituto de Química Médica (CSIC), Madrid, Spain.
[Ti] Título:Synthesis and preliminary pharmacological evaluation of thiophene analogues of viloxazine as potential antidepressant drugs.
[So] Source:Bioorg Med Chem;7(7):1349-59, 1999 Jul.
[Is] ISSN:0968-0896
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:A series of eight thienyloxymethylmorpholines, thiophene analogues of viloxazine, have been synthesized by three different routes. The preliminary pharmacological evaluation of this series shows antidepressant properties on the mice models used with a light sedative action. The structure-activity relationship is established in a first approximation.
[Mh] Termos MeSH primário: Antidepressivos/síntese química
Antidepressivos/farmacologia
Viloxazina/análogos & derivados
[Mh] Termos MeSH secundário: 5-Hidroxitriptofano/farmacologia
Animais
Apomorfina/toxicidade
Blefaroptose/induzido quimicamente
Blefaroptose/tratamento farmacológico
Relação Dose-Resposta a Droga
Feminino
Hipotermia/induzido quimicamente
Hipotermia/tratamento farmacológico
Imipramina/farmacologia
Dose Letal Mediana
Masculino
Camundongos
Transtornos dos Movimentos/tratamento farmacológico
Pentobarbital/farmacologia
Sono/efeitos dos fármacos
Relação Estrutura-Atividade
Tetrabenazina/toxicidade
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antidepressive Agents); 5I5Y2789ZF (Viloxazine); C1LJO185Q9 (5-Hydroxytryptophan); I4744080IR (Pentobarbital); N21FAR7B4S (Apomorphine); OGG85SX4E4 (Imipramine); Z9O08YRN8O (Tetrabenazine)
[Em] Mês de entrada:9910
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:990828
[St] Status:MEDLINE


  5 / 210 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:10422164
[Au] Autor:Carli P; Gisserot O; Marlier S; Paris JF
[Ad] Endereço:Service de médecine interne, HIA Sainte-Anne, Toulon Naval.
[Ti] Título:[Exasperating hematomas].
[Ti] Título:Des hématomes désespérants..
[So] Source:Rev Med Interne;20 Suppl 2:267s-268s, 1999.
[Is] ISSN:0248-8663
[Cp] País de publicação:France
[La] Idioma:fre
[Mh] Termos MeSH primário: Antidepressivos de Segunda Geração/efeitos adversos
Fluoxetina/efeitos adversos
Hemorragia Gastrointestinal/induzido quimicamente
Hematoma/induzido quimicamente
Inibidores da Captação de Serotonina/efeitos adversos
Dermatopatias/induzido quimicamente
[Mh] Termos MeSH secundário: Inibidores da Captação Adrenérgica/uso terapêutico
Idoso
Depressão/tratamento farmacológico
Feminino
Hemorragia/induzido quimicamente
Seres Humanos
Doença Iatrogênica
Reto
Síndrome
Viloxazina/uso terapêutico
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenergic Uptake Inhibitors); 0 (Antidepressive Agents, Second-Generation); 0 (Serotonin Uptake Inhibitors); 01K63SUP8D (Fluoxetine); 5I5Y2789ZF (Viloxazine)
[Em] Mês de entrada:9909
[Cu] Atualização por classe:161018
[Lr] Data última revisão:
161018
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:990728
[St] Status:MEDLINE


  6 / 210 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:10081591
[Au] Autor:Airaudo CB; Gayte-Sorbier A; Bianchi C
[Ad] Endereço:Department of Pharmacy, Valvert Hospital, Marseilles, France.
[Ti] Título:Comparative study of the sorption of clomipramine and viloxazine hydrochlorides in Stedim 6 and PVC bags.
[So] Source:Biomed Mater Eng;8(5-6):279-83, 1998.
[Is] ISSN:0959-2989
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:The stability of two antidepressant drugs, clomipramine and viloxazine hydrochlorides, was studied as was their possible sorption on Stedim 6, a new multilayer polyethylene-lined film, which was considered comparatively to polyvinyl chloride (PVC) and glass surfaces. Appropriate amounts of the drugs were added to 500 ml of 5% dextrose and 0.9% sodium chloride solutions in Stedim 6 and PVC bags, and in glass flasks, in order to obtain the concentrations currently used in clinical practice. All the containers were stored at room temperature in daylight for 72 hours. Samples were taken at various times and evaluated for remaining drug concentrations by UV spectrometry. The two drugs appeared stable under the given conditions. No concentration decrease was observed in glass flasks. Viloxazine hydrochloride showed an excellent compatibility with the PVC bags, but a slight concentration decrease (about 6-7% in 72 hours) was observed for clomipramine hydrochloride, depending on the contact duration. The compatibility of the two drugs with the new material Stedim 6 was found to be perfect. The behavioral differences observed between the two drugs with regard to PVC are explained in terms of differences of lipophilicity of the drugs. Those observed for a given drug with regard to the two materials are due to the crystalline structure of polyethylene and the amorphous one of PVC.
[Mh] Termos MeSH primário: Antidepressivos de Segunda Geração/química
Antidepressivos Tricíclicos/química
Clomipramina/química
Embalagem de Medicamentos
Polietilenos/química
Cloreto de Polivinila/química
Viloxazina/química
[Mh] Termos MeSH secundário: Adsorção
Cristalografia
Estabilidade de Medicamentos
Vidro/química
Infusões Intravenosas/instrumentação
Injeções Intravenosas/instrumentação
Luz
Lipídeos/química
Espectrofotometria Ultravioleta
Temperatura Ambiente
Fatores de Tempo
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antidepressive Agents, Second-Generation); 0 (Antidepressive Agents, Tricyclic); 0 (Lipids); 0 (Polyethylenes); 148709-77-7 (stedim 6); 5I5Y2789ZF (Viloxazine); 9002-86-2 (Polyvinyl Chloride); NUV44L116D (Clomipramine)
[Em] Mês de entrada:9905
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:990319
[St] Status:MEDLINE


  7 / 210 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:9715359
[Au] Autor:Lestra C; d'Amato T; Ghaemmaghami C; Perret-Liaudet A; Broyer M; Renaud B; Dalery J; Chamba G
[Ad] Endereço:Laboratoire de Biochimie, Hôpital Neurologique, Lyon, France.
[Ti] Título:Biological parameters in major depression: effects of paroxetine, viloxazine, moclobemide, and electroconvulsive therapy. Relation to early clinical outcome.
[So] Source:Biol Psychiatry;44(4):274-80, 1998 Aug 15.
[Is] ISSN:0006-3223
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Clinical and pharmacologic studies report a relative or absolute serotonergic deficiency in major depression; however, the variability of clinical characteristics of illness has led to controversial results. In the present work, we looked for a possible relationship between i) biochemical values that indirectly reflect aminergic neurons activity and clinical characteristics and ii) their evolution and the early clinical outcome under antidepressive therapies (ATs). METHODS: Platelet serotonin content, platelet monoamine oxydase activity, and urinary biopterins were measured in 27 depressed patients before and during four different ATs (paroxetine, viloxazine, moclobemide, or electroconvulsive therapy). Depressive symptomatology and its evolution under ATs were quantified using three clinical rating scales. RESULTS: A severe symptomatology, high serotonin (5-HT) platelet content, and high or low urinary B could represent risk factors leading to a smaller or delayed response to an AT. Furthermore, the early improvement under ATs was negatively correlated to pretreatment 5-HT platelet content. CONCLUSIONS: Determination of 5-HT level could be useful in the choice of an AT.
[Mh] Termos MeSH primário: Antidepressivos/farmacologia
Transtorno Depressivo/metabolismo
Transtorno Depressivo/terapia
Eletroconvulsoterapia
[Mh] Termos MeSH secundário: Inibidores da Captação Adrenérgica/farmacologia
Adulto
Idoso
Benzamidas/farmacologia
Biomarcadores
Biopterina/urina
Plaquetas/metabolismo
Resistência a Medicamentos
Feminino
Seres Humanos
Masculino
Meia-Idade
Moclobemida
Monoaminoxidase/metabolismo
Inibidores da Monoaminoxidase/farmacologia
Paroxetina/farmacologia
Estudos Prospectivos
Serotonina/sangue
Inibidores da Captação de Serotonina/farmacologia
Índice de Gravidade de Doença
Resultado do Tratamento
Viloxazina/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Adrenergic Uptake Inhibitors); 0 (Antidepressive Agents); 0 (Benzamides); 0 (Biomarkers); 0 (Monoamine Oxidase Inhibitors); 0 (Serotonin Uptake Inhibitors); 22150-76-1 (Biopterin); 333DO1RDJY (Serotonin); 41VRH5220H (Paroxetine); 5I5Y2789ZF (Viloxazine); EC 1.4.3.4 (Monoamine Oxidase); PJ0Y7AZB63 (Moclobemide)
[Em] Mês de entrada:9811
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:980826
[St] Status:MEDLINE


  8 / 210 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:9696909
[Au] Autor:Chebili S; Abaoub A; Mezouane B; Le Goff JF
[Ad] Endereço:Psychiatre des Hôpitaux, EPS Ville Evrard, Neuilly-sur-Marne.
[Ti] Título:[Antidepressants and sexual stimulation: the correlation].
[Ti] Título:Antidépresseurs et stimulation sexuelle: la part des choses..
[So] Source:Encephale;24(3):180-4, 1998 May-Jun.
[Is] ISSN:0013-7006
[Cp] País de publicação:France
[La] Idioma:fre
[Ab] Resumo:The purpose of this study is to correlate antidepressant treatment with sexual stimulation. The first part of this paper tries to describe some physiologic aspects of the sexual function. This complex subject includes several neuromediators which belong to adrenergic, cholinergic, dopaminergic and serotoninergic systems. A double-blind study shows that viloxazine, an atypical antidepressant, could act specifically on sex drive by desinhibiting effect. A precise study concludes that moclobemide improve significantly all components of sexual function. The numerous side effects of doxépine is a hindrance to its prescription. More precise studies about viloxazine and moclobemide suggest that both could have a specific effect on different components of sexual activity. In the second part of this paper, we consider the concept of "corrector". These drugs are numerous, however their prescriptions are not very wide spread: yohimbine, cyproheptadine, amantadine, bethanechol.
[Mh] Termos MeSH primário: Antidepressivos/uso terapêutico
Transtorno Depressivo/tratamento farmacológico
Libido/efeitos dos fármacos
Comportamento Sexual/efeitos dos fármacos
Disfunções Sexuais Psicogênicas/induzido quimicamente
[Mh] Termos MeSH secundário: Antidepressivos/efeitos adversos
Benzamidas/efeitos adversos
Benzamidas/uso terapêutico
Transtorno Depressivo/psicologia
Doxepina/efeitos adversos
Doxepina/uso terapêutico
Feminino
Seres Humanos
Masculino
Moclobemida
Disfunções Sexuais Psicogênicas/tratamento farmacológico
Estimulação Química
Viloxazina/efeitos adversos
Viloxazina/uso terapêutico
[Pt] Tipo de publicação:COMPARATIVE STUDY; ENGLISH ABSTRACT; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antidepressive Agents); 0 (Benzamides); 1668-19-5 (Doxepin); 5I5Y2789ZF (Viloxazine); PJ0Y7AZB63 (Moclobemide)
[Em] Mês de entrada:9810
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:980811
[St] Status:MEDLINE


  9 / 210 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:9387086
[Au] Autor:Bouchard JM; Strub N; Nil R
[Ad] Endereço:C.H.S. Gérard Marchant, Toulouse, France.
[Ti] Título:Citalopram and viloxazine in the treatment of depression by means of slow drop infusion. A double-blind comparative trial.
[So] Source:J Affect Disord;46(1):51-8, 1997 Oct.
[Is] ISSN:0165-0327
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Antidepressant efficacy and tolerability of citalopram and viloxazine were compared under double-blind conditions during the first two weeks of treatment with slow drop infusion, followed by oral administration for the rest of the six week trial period. The 62 severely depressed and hospitalised patients included in the intention-to-treat analysis had a mean age of 45 years (range 23 to 70 years). About two thirds of the patients were female. Thirty patients were allocated to the citalopram and 32 patients to the viloxazine group. The mean MADRS total score at baseline was 34 in both groups and decreased to 12.3 in the citalopram and to 16.9 in the viloxazine group after 14 days of infusion. On day 42 (end point) the scores dropped to 6.7 in the citalopram and to 13.1 in the viloxazine group respectively. The group differences reached the level of significance at both time points (p < 0.05) in favour of citalopram. The analysis of treatment emergent adverse events based on the UKU scale showed a higher frequency of nausea on day 14 and constipation at study end in the viloxazine group (p < 0.05) whereas reported weight gain (day 21) and concentration difficulty (day 21) were more frequently seen in the citalopram group (p < 0.05). Standard laboratory investigations and ECG analyses did not show clinically relevant abnormalities. It is concluded that antidepressant treatment with citalopram infusion followed by oral citalopram may be more efficacious than a corresponding treatment schedule with viloxazine.
[Mh] Termos MeSH primário: Antidepressivos de Segunda Geração/administração & dosagem
Antidepressivos/administração & dosagem
Citalopram/administração & dosagem
Transtorno Depressivo Maior/tratamento farmacológico
Viloxazina/administração & dosagem
[Mh] Termos MeSH secundário: Administração Oral
Adulto
Idoso
Antidepressivos/efeitos adversos
Antidepressivos de Segunda Geração/efeitos adversos
Citalopram/efeitos adversos
Transtorno Depressivo Maior/diagnóstico
Transtorno Depressivo Maior/psicologia
Método Duplo-Cego
Esquema de Medicação
Feminino
Seres Humanos
Infusões Intravenosas
Masculino
Meia-Idade
Inventário de Personalidade
Resultado do Tratamento
Viloxazina/efeitos adversos
[Pt] Tipo de publicação:CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Antidepressive Agents); 0 (Antidepressive Agents, Second-Generation); 0DHU5B8D6V (Citalopram); 5I5Y2789ZF (Viloxazine)
[Em] Mês de entrada:9801
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:971205
[St] Status:MEDLINE


  10 / 210 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:8881130
[Au] Autor:Py P; Danel V
[Ti] Título:[Acute agitation after poisoning to viloxazine].
[Ti] Título:Etat d'agitation aiguë après intoxication à la viloxazine..
[So] Source:Therapie;51(3):327, 1996 May-Jun.
[Is] ISSN:0040-5957
[Cp] País de publicação:France
[La] Idioma:fre
[Mh] Termos MeSH primário: Acatisia Induzida por Medicamentos/etiologia
Antidepressivos de Segunda Geração/envenenamento
Viloxazina/envenenamento
[Mh] Termos MeSH secundário: Adulto
Feminino
Seres Humanos
[Pt] Tipo de publicação:CASE REPORTS; LETTER
[Nm] Nome de substância:
0 (Antidepressive Agents, Second-Generation); 5I5Y2789ZF (Viloxazine)
[Em] Mês de entrada:9612
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:960501
[St] Status:MEDLINE



página 1 de 21 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde